Are thermogenic proteins and adipokine chemerin affected by monoclonal antibody therapy in asthma?

Bulut T., Yalcin A. D., ÇELİK B., Genc G. E., GÖÇMEN A. Y., GÜMÜŞLÜ S.

EURASIAN JOURNAL OF PULMONOLOGY, vol.21, no.3, pp.161-166, 2019 (ESCI) identifier

  • Publication Type: Article / Article
  • Volume: 21 Issue: 3
  • Publication Date: 2019
  • Doi Number: 10.4103/ejop.ejop_60_18
  • Journal Indexes: Emerging Sources Citation Index (ESCI), TR DİZİN (ULAKBİM)
  • Page Numbers: pp.161-166
  • Keywords: Asthma, CD16-56, CD80, chemerin, interleukin-1 beta, irisin, natural killer activity, omalizumab, ALLERGIC-ASTHMA, DISEASE, OMALIZUMAB, WEAKNESS, IRISIN, COPD
  • Akdeniz University Affiliated: Yes


BACKGROUND: Irisin is a thermogenic protein that sources outgoing energy by converting white adipose tissue to brown adipose tissue. Chemerin is originally identified as a chemoattractant protein that mainly mediating the chemotaxis of dendritic cells and natural killer cells (NKCs). The aim of this study is to assess the potential impact of immune modulation-related chemerin and irisin concentrations together with cell surface markers (CSM) in allergic asthmatic patients under omalizumab treatment.